SCHEMBL2878253

SCHEMBL2878253

CC1=CCC(C(=O)Cl)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.58
TSHR P16473 4/20 0.40
TAS2R46 P59540 6/20 0.37
ALDH1A1 P00352 2/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TRPA1 O75762 1/20 0.36
TAS2R31 P59538 2/20 0.35
TAS2R10 Q9NYW0 2/20 0.35
ALOX15 P16050 4/20 0.35
CYP3A4 P08684 2/20 0.35
PTPN1 P18031 1/20 0.35
MEN1 O00255 1/20 0.33
MAPK1 P28482 1/20 0.33
KMT2A Q03164 1/20 0.33
CHRNA7 P36544 1/20 0.33
STAT3 P40763 1/20 0.33
CYP1B1 Q16678 1/20 0.33
TP53 P04637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2220574 1.00 LMNA (0.58) LMNATSHRTAS2R46ALDH1A1NPC1
SCHEMBL937997 1.00 LMNA (0.58) LMNATSHRTAS2R46ALDH1A1NPC1
Valine SCHEMBL15477725 0.83 LMNA (0.46) LMNATSHRALDH1A1NPC1RAB9A
SCHEMBL937318 0.82 LMNA (0.60) LMNATSHRTAS2R46ALDH1A1NPC1
SCHEMBL1037667 0.82 LMNA (0.60) LMNATSHRTAS2R46ALDH1A1NPC1
SCHEMBL937050 0.82 LMNA (0.60) LMNATSHRTAS2R46ALDH1A1NPC1
SCHEMBL12909964 0.82 LMNA (0.66) LMNATSHRTAS2R46ALDH1A1NPC1
SCHEMBL1783157 0.82 LMNA (0.66) LMNATSHRTAS2R46ALDH1A1NPC1
SCHEMBL15450107 0.82 LMNA (0.66) LMNATSHRTAS2R46ALDH1A1NPC1
SCHEMBL23128326 0.80 LMNA (0.58) LMNATSHRTAS2R46ALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4725279-A1 ORGANIC HETEROCYCLES FOR PHOTOELECTRIC DEVICES Merck Patent GmbH (DE) 2026-04-15 EP disclosed
EP-4541156-A1 ORGANIC HETEROCYCLES FOR PHOTOELECTRIC DEVICES Merck Patent GmbH (DE) 2025-04-23 EP disclosed
CN-119325755-A Organic heterocyclic compounds for optoelectronic devices 默克专利有限公司 2025-01-17 CN disclosed
WO-2024256357-A1 ORGANIC HETEROCYCLES FOR PHOTOELECTRIC DEVICES MERCK PATENT GMBH (DE) 2024-12-19 WO disclosed
WO-2023247338-A1 ORGANIC HETEROCYCLES FOR PHOTOELECTRIC DEVICES MERCK PATENT GMBH (DE) 2023-12-28 WO disclosed
WO-2017184549-A1 PYRROLOPYRIDINE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF INNOV17 LLC (US) 2017-10-26 WO disclosed
EP-3219713-A1 INHIBITORS OF FLAVIVIRIDAE VIRUSES Gilead Sciences, Inc. (US) 2017-09-20 EP disclosed
EP-2523950-B1 INHIBITORS OF FLAVIVIRIDAE VIRUSES GILEAD SCIENCES INC (US) 2017-03-15 EP disclosed
US-9321753-B2 Inhibitors of Flaviviridae viruses GILEAD SCIENCES, INC. (US) 2016-04-26 US disclosed
EP-2734515-B1 THIOPHEN-2-CARBOXYLIC ACID DERIVATIVES USEFUL AS INHIBITORS OF FLAVIVIRIDAE VIRUSES GILEAD SCIENCES INC (US) 2015-11-04 EP disclosed
EP-1569929-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF i FLAVIVIRUS /i INFECTIONS Virochem Pharma Inc. (CA) 2005-09-07 EP disclosed
US-20050009804-A1 Compounds and methods for the treatment or prevention of Flavivirus infections VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) 2005-01-13 US disclosed
EP-1159258-B1 AMIDE COMPOUNDS FOR THE POTENTIATION OF CHOLINERGIC ACTIVITY FUJISAWA PHARMACEUTICAL CO (JP) 2004-11-10 EP disclosed
US-20040167315-A1 Active energy ray curable composition KONICA MINOLTA HOLDINGS, INC. (JP) 2004-08-26 US disclosed
WO-2004052885-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VIROCHEM PHARMA INC. (CA) 2004-06-24 WO disclosed
US-20040048904-A1 Amide compounds for the potentiation of cholinergic activity FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2004-03-11 US disclosed
US-6664293-B2 For treatment and/or prevention of disorders in the central nervous system, particularly amnesia, dementia, Alzheimer's dementia FUJIWAWA PHARMACEUTICAL CO., LTD. (JP) 2003-12-16 US disclosed
US-20030096847-A1 Amide compounds for the potentiation of cholinergic activity FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-05-22 US disclosed
EP-1159258-A1 AMIDE COMPOUNDS FOR THE POTENTIATION OF CHOLINERGIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-12-05 EP disclosed
WO-2000051970-A1 AMIDE COMPOUNDS FOR THE POTENTIATION OF CHOLINERGIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-09-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009804-A1 Compounds and methods for the treatment or prevention of Flavivirus infections ZC3HAV1, ZYX, ZFX LMNA 1242/4885TSHR 4286/4885TAS2R46 3695/4885
US-20040048904-A1 Amide compounds for the potentiation of cholinergic activity CHAT, CHRM2, CHRNA2 LMNA 2903/4885TSHR 691/4885TAS2R46 3351/4885
US-20030096847-A1 Amide compounds for the potentiation of cholinergic activity CHAT, CHRM2, CHRNA2 LMNA 2903/4885TSHR 691/4885TAS2R46 3351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.